Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

Linglong Yin; Youhong Liu; Yuchong Peng; Yongbo Peng; Xiaohui Yu; Yingxue Gao; Bowen Yuan; Qianling Zhu; Tuoyu Cao; Leye He; Zhicheng Gong; Lunquan Sun; Xuegong Fan; Xiong Li

doi:10.1186/s13046-022-02290-9

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

J Exp Clin Cancer Res. 2022 Feb 22;41(1):72. doi: 10.1186/s13046-022-02290-9.

Authors

Linglong Yin^{1

2}, Youhong Liu^{1

2}, Yuchong Peng^{1

2}, Yongbo Peng³, Xiaohui Yu^{1

2}, Yingxue Gao^{1

2}, Bowen Yuan^{1

2}, Qianling Zhu^{1

2}, Tuoyu Cao^{1

2}, Leye He⁴, Zhicheng Gong⁵, Lunquan Sun^{1

2}, Xuegong Fan⁶, Xiong Li^{7

8

9}

Affiliations

¹ Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
² Hunan Key Laboratory of Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China.
³ State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China.
⁴ Research Institute for Prostate Disease, Central South University, Changsha, China.
⁵ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
⁶ Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China.
⁷ Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. lixiongxiangya@csu.edu.cn.
⁸ Hunan Key Laboratory of Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China. lixiongxiangya@csu.edu.cn.
⁹ Research Institute for Prostate Disease, Central South University, Changsha, China. lixiongxiangya@csu.edu.cn.

No abstract available

Publication types

Published Erratum